Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study
Joan L Walker, Marion R Piedmonte, Nick M Spirtos, et al.
Gynecologic Oncology
|
July 17, 2012
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study
D Scott McMeekin, Michael W Sill, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2
Joan L Walker, Marion R Piedmonte, Nick M Spirtos, et al.
Gynecologic Oncology
|
September 18, 2010
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A Hurteau, Mark F Brady, Kathleen M Darcy, et al.
American Journal of Obstetrics and Gynecology
|
October 18, 2017
Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study
Erin A Bishop, James J Java, Kathleen N Moore, et al.
Gynecologic Oncology
|
March 19, 2017
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Yvette W Jeske, Shamshad Ali, Sara A Byron, et al.
Gynecologic Oncology
|
August 27, 2023
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women
Ian S Hagemann, Wei Deng, Richard J Zaino, et al.
JAMA Oncology
|
December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial
Debra L Richardson, Michael W Sill, Robert L Coleman, et al.
Gynecologic Oncology
|
January 11, 2021
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women
Ian S Hagemann, Wei Deng, Richard J Zaino, et al.
Gynecologic Oncology
|
October 17, 2016
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis
Amanda N Fader, James Java, Meaghan Tenney, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study
Joan L Walker, Marion R Piedmonte, Nick M Spirtos, et al.
Gynecologic Oncology
|
July 17, 2012
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study
D Scott McMeekin, Michael W Sill, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2
Joan L Walker, Marion R Piedmonte, Nick M Spirtos, et al.
Gynecologic Oncology
|
September 18, 2010
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A Hurteau, Mark F Brady, Kathleen M Darcy, et al.
American Journal of Obstetrics and Gynecology
|
October 18, 2017
Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study
Erin A Bishop, James J Java, Kathleen N Moore, et al.
Gynecologic Oncology
|
March 19, 2017
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Yvette W Jeske, Shamshad Ali, Sara A Byron, et al.
Gynecologic Oncology
|
August 27, 2023
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women
Ian S Hagemann, Wei Deng, Richard J Zaino, et al.
JAMA Oncology
|
December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial
Debra L Richardson, Michael W Sill, Robert L Coleman, et al.
Gynecologic Oncology
|
January 11, 2021
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women
Ian S Hagemann, Wei Deng, Richard J Zaino, et al.
Gynecologic Oncology
|
October 17, 2016
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis
Amanda N Fader, James Java, Meaghan Tenney, et al.
Page
of 7